Skip to main content

Table 1 Characteristics of the development and validation datasets

From: Predicting 2-year survival in stage I-III non-small cell lung cancer: the development and validation of a scoring system from an Australian cohort

Characteristic

Development cohort (n = 117)

Validation cohort (n = 144)

p-value†

n (%)

n (%)

Sex

  

0.1

 Male

79 (67.5)

83 (57.6)

 

 Female

38 (32.5)

61 (42.4)

 

Age (years)

  

0.31

 Median (range)

73 (34–90)

74 (45–91)

 

ECOG performance status

  

0.025

 0

55 (47.0)

44 (30.6)

 

 1

35 (29.9)

61 (42.4)

 

 ≥ 2

27 (23.1)

36 (25.0)

 

 Unknown

0 (0)

3 (2.1)

 

SCS

  

0.16

 0–9

77 (65.8)

104 (72.2)

 

 10–20

40 (34.2)

37 (35.6)

 

 Unknown

0 (0)

3 (2.1)

 

Smoking status

  

0.53

 Current

38 (32.5)

37 (25.7)

 

 Past

71 (60.7)

93 (64.6)

 

 Never

7 (6.0)

10 (6.9)

 

 Unknown

1 (0.9)

4 (2.8)

 

Pack years smoked

  

0.7

 Median (range)

40 (0–150)

40 (0–150)

 

 Unknown

7 (6.0)

7 (4.9)

 

Weight loss (%)

  

 < 0.001

 None

57 (48.7)

41 (28.5)

 

 ≤ 10

29 (24.8)

51 (35.4)

 

 > 10

25 (21.4)

7 (4.9)

 

 Unknown

6 (5.1)

45 (31.3)

 

FEV1 (%)

  

0.19

 Median (range)

68 (25–121)

68 (30–133)

 

 Unknown

16 (13.7)

36 (25.0)

 

DLCO (%)

  

0.5

 Median (range)

60 (28–115)

58 (28–134)

 

 Unknown

24 (20.5)

84 (58.3)

 

Overall stage

  

0.016

 I

34 (29.1)

62 (43.1)

 

 II

22 (18.8)

13 (9.0)

 

 III

61 (52.1)

69 (47.9)

 

T stage

  

0.086

 T1

31 (26.5)

54 (37.5)

 

 T2

38 (32.5)

52 (36.1)

 

 T3

33 (28.2)

25 (17.4)

 

 T4

14 (12.0)

13 (9.0)

 

 Unknown

1 (0.9)

0 (0)

 

N stage

  

0.065

 N0

56 (47.9)

79 (54.9)

 

 N1

14 (12.0)

5 (3.5)

 

 N2

31 (26.5)

42 (29.2)

 

 N3

16 (13.7)

18 (12.5)

 

Histological diagnosis

  

0.034

 Squamous cell carcinoma

64 (54.7)

24 (16.7)

 

 Adenocarcinoma

37 (31.6)

45 (31.3)

 

 Other

16 (13.7)

69 (47.9)

 

Tumour grade

  

0.11

 < 3

36 (30.8)

24 (16.7)

 

 3

39 (33.3)

45 (31.3)

 

 Unknown

42 (35.9)

75 (52.1)

 

Tumour laterality

  

0.23

 Left

48 (41.0)

71 (49.3)

 

 Right

67 (57.3)

73 (50.7)

 

 Unknown

2 (1.7)

0 (0)

 

Tumour lobe

  

0.76

 Upper

71 (60.7)

86 (59.7)

 

 Middle/lower

44 (37.6)

57 (39.6)

 

 Unknown

2 (1.7)

1 (0.7)

 

GTV (cc)

  

0.32

 Median (range)

49.8 (0.7–1039.0)

23 (1.7–1065.0)

 

 Unknown

26 (22.2)

29 (20.1)

 

Mutation status

  

0.28

 EGFR positive

4 (3.4)

8 (5.6)

 

 ALK positive

1 (0.9)

2 (1.4)

 

 None

36 (30.8)

30 (20.8)

 

 Unknown

76 (65.0)

104 (72.2)

 

PD-L1 status (%)

  

0.45

 < 1

4 (3.4)

2 (1.4)

 

 1–49

8 (6.8)

4 (2.8)

 

 ≥ 50

5 (4.3)

2 (1.4)

 

 Unknown

100 (85.5)

136 (94.4)

 

Radiotherapy technique

  

 < 0.001

 Conformal

15 (12.8)

80 (55.6)

 

 IMRT

80 (68.4)

24 (16.7)

 

 VMAT

22 (18.8)

39 (27.1)

 

 Unknown

0 (0)

1 (0.7)

 

Radiotherapy treatment duration (days)

  

0.37

 Median (range)

26 (1–47)

22 (1–48)

 

EQD2 (Gy)

  

0.12

 Median (range)

60 (12–126)

60 (6.3–88)

 

Chemotherapy use

  

0.18

 Chemotherapy

45 (38.5)

44 (30.6)

 

 No chemotherapy

72 (61.5)

100 (69.4)

 

Survival time (months)

  

0.011

 Median (range)

17 (1–44)

22 (0–46)

 

2-year status

  

0.92

 Alive

56 (47.9)

68 (47.2)

 

 Dead

61 (52.1)

76 (52.8)

 
  1. ECOG = Eastern Cooperative Oncology Group; SCS = Simplified Comorbidity Score; FEV1 = forced expiratory volume in 1 s; DLCO = diffusing capacity of the lung for carbon monoxide; GTV = gross tumour volume; EGFR = epidermal growth factor receptor; ALK = anaplastic lymphoma kinase, PD-L1 = programmed death-ligand 1; IMRT = intensity-modulated radiotherapy; VMAT = volumetric modulated arc therapy; EQD2 = equivalent dose in 2 Gy fractions
  2. †Comparison of development and validation cohort
Back to article page

Radiation Oncology

ISSN: 1748-717X

Contact us